IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

Corporate Breaking News

Home : IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

Feb 25 2020	IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer
COPENHAGEN, Denmark, Feb. 25, 2020 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing...


Source:https://www.prnewswire.com:443/news-releases/io-biotech-announces-positive-outcome-of-interim-analysis-of-phase-2-randomized-trial-in-first-line-non-small-cell-lung-cancer-301010051.html

Related News
» ANA HOLDINGS Commits to Adding up to 20 Boeing 787 Dreamliner Jets » Covariant and ABB Partner to Deploy Integrated AI Robotic Solutions